On June 13, The Supreme Court announced its unanimous decision in FDA vs. Alliance for Hippocratic Medicine, governing access to a critical drug used in medication (non-surgical) abortions and to manage miscarriages. The decision preserves access (for now) to the widely used drug mifepristone, currently legal in 36 states. The court decided the case on procedural grounds, concluding that the plaintiffs, a coalition of anti-abortion physicians and medical associations, lacked standing. [time-brightcove not-tgx=”true”] Reproductive-justice advocates cautioned that challenges to the availability of the drug are likely to make their way back to the court, threatening access to a medication that has proved extraordinarily safe and effective. Yet this case goes far beyond issues of legal standing and procedure.